Lanreotide
Clinical data | |
---|---|
[[Regulation of therapeutic goods |Template:Engvar data]] |
|
Pregnancy category | |
Routes of administration | Intramuscular, subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Approximately 80%[1] |
Protein binding | 78%[1] |
Metabolism | In GI tract |
Elimination half-life | 2 hours (immediate release) 5 days (sustained release) |
Excretion | Mostly biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C54H69N11O10S2 |
Molar mass | 1096.33 g/mol 1156.380 g/mol (acetate) |
WikiDoc Resources for Lanreotide |
Articles |
---|
Most recent articles on Lanreotide |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Lanreotide at Clinical Trials.gov Clinical Trials on Lanreotide at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Lanreotide
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Lanreotide Discussion groups on Lanreotide Patient Handouts on Lanreotide Directions to Hospitals Treating Lanreotide Risk calculators and risk factors for Lanreotide
|
Healthcare Provider Resources |
Causes & Risk Factors for Lanreotide |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide.
Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30 2007.[2]
Pharmacology
Lanreotide is a synthetic analogue of somatostatin, a naturally-occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. However, while somatostatin is quickly broken down in the body (within minutes),[3] lanreotide has a much longer half-life, and produces far more prolonged effects.
The efficacy of lanreotide has not been extensively studied, and results differ greatly between trials and formulations.
Indications
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,[4] a rare tumor of the pituitary gland which secretes TSH.
Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.[5][6]
Side effects
The main side effects of lanreotide treatment are mild to moderate pain at the injection site and gastrointestinal disturbances, such as diarrhea, nausea and vomiting. Isolated cases of gallstone formation have been associated with use of lanreotide, particularly over long periods of time.[1][4]
Formulations
Lanreotide is available in two formulations: a sustained release formulation (sold under the trade name Somatuline LA), which is injected intramuscularly every ten or fourteen days,[4] and an extended release formulation (UK trade name Somatuline Autogel, or Somatuline Depot in the U.S.), which is administered subcutaneously once a month.[7]
References
- ↑ 1.0 1.1 1.2 Template:Fr icon "Lanreotide Acetate". BIAM. March 5, 2001. Retrieved 2007-03-02.
- ↑ "FDA Approves New Drug to Treat Rare Disease, Acromegaly" (Press release). U.S. Food and Drug Administration. August 30 2007. Retrieved 2007-09-06. Check date values in:
|date=
(help) - ↑ Rens-Domiano S, Reisine T (1992). "Biochemical and functional properties of somatostatin receptors". J Neurochem. 58 (6): 1987&ndash, 96. doi:10.1111/j.1471-4159.1992.tb10938.x. PMID 1315373.
- ↑ 4.0 4.1 4.2 "Somatuline LA". electronic Medicines Compendium. September 17, 2003. Retrieved 2007-03-02.
- ↑ Kvols L, Woltering E (2006). "Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors". Anticancer Drugs. 17 (6): 601&ndash, 8. PMID 16917205.
- ↑ Susini C, Buscail L (2006). "Rationale for the use of somatostatin analogs as antitumor agents". Ann Oncol. 17 (12): 1733&ndash, 42. PMID 16801334.
- ↑ "Somatuline Autogel". electronic Medicines Compendium. April 12, 2007. Retrieved 2007-04-19.
- Pages with script errors
- CS1 errors: dates
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Peptides
- Hormonal agents
- Endocrinology